- Library Home /
- Search Collections /
- Open Collections /
- Browse Collections /
- UBC Faculty Research and Publications /
- Expression patterns of the immune checkpoint ligand...
Open Collections
UBC Faculty Research and Publications
Expression patterns of the immune checkpoint ligand CD276 in urothelial carcinoma Aicher, Wilhelm K; Korn, M.; Reitnauer, L.; Maurer, F. B; Hennenlotter, J.; Black, Peter C.; Todenhofer, T.; Bedke, J.; Stenzl, A.
Abstract
Background: CD276 is an immune checkpoint molecule. Elevated CD276 expression by urothelial carcinoma is associated with poor prognosis, but little is known about its expression across different tumor stages. We therefore investigated CD276 expression in bladder cancer (BC) cells and in tissue samples of BC stages from pT2 to pT4. Methods: CD276 expression was explored in 4 urothelial cancer cell lines and 4 primary normal urothelial cell populations by quantitative RT-PCR, Western blot and flow cytometry. CD276 was investigated in bladder tumors from 98 patients by immunohistochemistry using a score (0–300) incorporating both, staining intensity and area of CD276 staining. Normal appearing urothelium in the bladder of the same patients served as controls. Results: The urothelial carcinoma cell lines expressed significantly higher levels of CD276 on transcript (p
Item Metadata
| Title | Expression patterns of the immune checkpoint ligand CD276 in urothelial carcinoma |
| Creator | Aicher, Wilhelm K; Korn, M.; Reitnauer, L.; Maurer, F. B; Hennenlotter, J.; Black, Peter C.; Todenhofer, T.; Bedke, J.; Stenzl, A. |
| Contributor |
Vancouver Prostate Centre |
| Publisher | BioMed Central |
| Date Issued | 2021-04-12 |
| Description |
Background:
CD276 is an immune checkpoint molecule. Elevated CD276 expression by urothelial carcinoma is associated with poor prognosis, but little is known about its expression across different tumor stages. We therefore investigated CD276 expression in bladder cancer (BC) cells and in tissue samples of BC stages from pT2 to pT4.
Methods:
CD276 expression was explored in 4 urothelial cancer cell lines and 4 primary normal urothelial cell populations by quantitative RT-PCR, Western blot and flow cytometry. CD276 was investigated in bladder tumors from 98 patients by immunohistochemistry using a score (0–300) incorporating both, staining intensity and area of CD276 staining. Normal appearing urothelium in the bladder of the same patients served as controls.
Results:
The urothelial carcinoma cell lines expressed significantly higher levels of CD276 on transcript (p
|
| Subject | Urothelial carcinoma; Immune check-point protein; CD276; B7-H3; Bladder tumor stages |
| Genre | Article |
| Type | Text |
| Language | eng |
| Date Available | 2021-04-14 |
| Provider | Vancouver : University of British Columbia Library |
| Rights | Attribution 4.0 International (CC BY 4.0) |
| DOI | 10.14288/1.0396701 |
| URI | |
| Affiliation | Other UBC; Non UBC |
| Citation | BMC Urology. 2021 Apr 12;21(1):60 |
| Publisher DOI | 10.1186/s12894-021-00829-0 |
| Peer Review Status | Reviewed |
| Scholarly Level | Faculty |
| Copyright Holder | The Author(s) |
| Rights URI | |
| Aggregated Source Repository | DSpace |
Item Media
Item Citations and Data
License
Attribution 4.0 International (CC BY 4.0)